# openai / gpt-5 / pass1_contradictions

I found several pairs of incompatible statements about the same facts. For each pair I list the two statements (quoted), where they appear (file path and section), and what would have to be true for both to hold at once.

- Metformin tested in trisomic cells vs “never tested” for aneuploidy-selective killing
  - “AMPK activation; impaired accumulation of trisomy 13 and 16 cells in culture, alongside AICAR [Shown; Tang 2011].”
    - File: track2/research/02_clinical_care_drugs.md, section 5 (table row “Metformin”)
  - “01 §4.2 records that no study tests metformin for aneuploidy-selective killing.”
    - File: archive/panel2/round1_labgeneticist.md, “Ranked candidates,” item 4
  - For both to hold at once: “aneuploidy-selective killing” would have to be read narrowly (e.g., not counting Tang’s 72-hour “impaired accumulation” in mouse MEFs as “selective killing,” or restricting the claim to human or patient cells), while acknowledging that metformin was in fact tested in trisomic mouse MEFs at 0.5–1.0 mM.

- Dasatinib powder for oral suspension: US availability vs not available in US
  - “Powder for oral suspension 10 mg/mL (Sprycel PFOS, emc 10228; US), licensed from age 1: the only giveable form at 15 kg. No compounding while a licensed liquid exists.”
    - File: archive/panel2/round1_pharmacologist.md, “Dasatinib” (formulations paragraph)
  - “Authorised in the EU (X/0056/G, Commission Decision 2 July 2018) and NOT in the US, where every product on record is a tablet and the sub-10 kg exclusion has no alternative offered.”
    - File: archive/creative/I_pharmacist.md, “Dasatinib” (formulations paragraph and the “US vs EU” note)
  - For both to hold at once: either a US approval of the PFOS would have to exist but not be reflected in openFDA/Drugs@FDA at the time (unlikely), or the “US” tag in the first statement was a mislabel for the EU product (i.e., “licensed” refers to the EU, and “US” was an error). Alternatively, the pharmacy seat’s line would have to be read as “available in practice by compounding,” not “licensed,” but the text says “licensed.”

- RMS 2005 overall survival figures (85.0/72.4 vs 86.5/73.7)
  - “5-year overall survival 85.0 percent (95 percent CI 80.2 to 90.9) against 72.4 percent (65.8 to 80.1), HR 0.52 (0.32 to 0.86), p=0.0097.”
    - File: archive/panel2/round1_predispositiononcologist.md, “Ranked candidates,” item 1 (carve-out paragraph)
  - “5-year overall survival 86.5 percent (95 percent CI 80.2 to 90.9) against 73.7 percent (65.8 to 80.1), HR 0.52 (0.32 to 0.86), p=0.0097.”
    - File: REPORT_track2.md, section 5 and repeated in section 6
  - For both to hold at once: the two figures would have to refer to different analyses (e.g., an earlier summary vs the final published ITT OS), or one would have to be a misquote of the same endpoint. As printed, both cannot simultaneously be correct for the same analysis.

- 731X allele identity (nonsense vs splice-acceptor frameshift)
  - “Stabilise the nonsense transcript on purpose and accept the truncated protein … Suijkerbuijk 2012 … a BUBR1 protein truncated at 731 … restores chromosome alignment …”
    - File: archive/creative/A_allele_expression_segregation.md, “Ranked ideas,” item 1
  - “The 731X allele is not a nonsense allele. Found in revision … 731X is the splice-acceptor mutation IVS16-2A>G, p.Ser714fsTer731 … It still supports the proposition that a BUBR1 protein lacking the kinase domain is functional when it is expressed; it does not support any stop-codon readthrough argument for p.ALLELE_A.”
    - File: REPORT_track2.md, section 2 (“A correction, and a further correction found in revision.”)
  - For both to hold at once: the term “nonsense transcript” in the first must be read loosely as “transcript carrying a premature termination” rather than the strict mechanism (PTC within a coding exon), and the therapeutic NMD premise must apply regardless of whether the trigger is a splice-acceptor frameshift or a coding PTC.

- Ataluren availability (“unobtainable” vs special-access routes exist)
  - “Ataluren, unobtainable.”
    - File: archive/panel2/round1_labgeneticist.md, “Excluded, one line each”
  - “Not authorised outside Great Britain, obtainable elsewhere only by named-patient import or single-patient IND (Great Britain PLGB 44221/0004, renewed 24/02/2026, after the European Commission declined to renew the EU conditional authorisation on 28 March 2025).”
    - File: REPORT_track2.md, section 7 (“Explicitly not recommended, and why”)
  - For both to hold at once: “unobtainable” must be understood as “not obtainable through normal local channels” (routine prescribing or standard hospital stock), while acknowledging that named-patient import or single-patient IND are possible but exceptional routes.

- Hydroxychloroquine retinopathy: “low under age five” vs “no paediatric screening guideline; screening may be unperformable”
  - “Retinopathy risk is low under age five but needs an eye exam, and MVA already carries ocular anomalies, so that visit may exist.”
    - File: archive/panel/round1_family.md, “Ranked list,” item 3 (Hydroxychloroquine)
  - “No paediatric retinopathy screening guideline; retinal exam at baseline, yearly from 5 years or earlier with reduced renal function … which may not be performable at this age.”
    - File: archive/creative/I_pharmacist.md, “Hydroxychloroquine” (monitoring paragraph)
  - For both to hold at once: “low under age five” must refer to short cumulative treatment durations rather than a child’s chronological age (i.e., risk is duration-dependent), while also accepting that formal paediatric screening guidance is lacking and practical access to reliable baseline and follow-up exams may be limited in young or developmentally delayed children.

- Sirolimus formulation (no paediatric formulation vs oral solution exists)
  - “Sirolimus: same mechanism as everolimus without the paediatric formulation.”
    - File: archive/panel/round1_geneticist.md, “Excluded” list
  - “Oral solution 1 mg/mL (Rapamune, generics, EU and US) … No compounding.”
    - File: archive/creative/I_pharmacist.md, “Sirolimus” (formulations)
  - For both to hold at once: “without the paediatric formulation” must be interpreted as “without a paediatric-labelled indication/formulation matching everolimus dispersible tablets for TSC,” while accepting that an oral solution exists (but is not an approved paediatric indication for MVA-related uses).

- BUB1B metformin claim: “impaired accumulation” vs “no study tests metformin for aneuploidy-selective killing”
  - “Metformin … impaired the accumulation of trisomy 13 and 16 cells in culture, alongside AICAR [Shown; Tang 2011].”
    - File: track2/research/02_clinical_care_drugs.md, section 5 (table row “Metformin”)
  - “01 §4.2 records that no study tests metformin for aneuploidy-selective killing.”
    - File: archive/panel2/round1_geneticist.md, “Ranked candidates,” item 4
  - For both to hold at once: the first must be taken as a report of a 72-hour “impaired accumulation” result in mouse MEFs, while the second reads “no study tests selective killing” literally (e.g., no human/patient-cell killing at clinically reachable concentrations) or restricts the claim to BubR1 models or in vivo systems.

If you want me to scan for more pairs across other sections, I can extend this list.
